"Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?"
This commentary argues that Pfizer's high dividend yield is at risk due to upcoming patent expirations on key drugs and a lack of new blockbusters in the pipeline. It contends that the company's substantial dividend payments may not be sustainable if revenue declines from generic competition are not offset by new drug approvals.